echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > With more than 20 billion yen of cooperation, Roche's Sino-foreign pharmaceuticals have deepened the layout of CAR-T

    With more than 20 billion yen of cooperation, Roche's Sino-foreign pharmaceuticals have deepened the layout of CAR-T

    • Last Update: 2022-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 22, Roche's Chugai Pharmaceutical and Noile-Immune Biotech jointly announced that they have signed a licensing agreement for Noile-Immune's proprietary PRIME CAR-T technology, which aims to use PRIME technology and Chugai's drug discovery technology to provide CAR-T cell therapy


    The agreement is based on the results


    CAR-T cell therapy has achieved significant success in the treatment of hematological tumors, but such cell therapies still face many challenges in the treatment of solid tumors, such as limited specific targets of solid tumors, difficulty of CAR-T cells infiltrating into solid tumors


    Noile-Immune's PRIME technology promises to open up a new generation of CAR-T cell therapies that will not only be used in blood tumors, but also to treat solid tumors


    Image credit: Noile-Immune.


    Dr.


    Original English:

    Original English:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.